BRPI0518760A8 - sal de potássio do composto, e, composição farmacêutica - Google Patents

sal de potássio do composto, e, composição farmacêutica

Info

Publication number
BRPI0518760A8
BRPI0518760A8 BRPI0518760A BRPI0518760A BRPI0518760A8 BR PI0518760 A8 BRPI0518760 A8 BR PI0518760A8 BR PI0518760 A BRPI0518760 A BR PI0518760A BR PI0518760 A BRPI0518760 A BR PI0518760A BR PI0518760 A8 BRPI0518760 A8 BR PI0518760A8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
potassium salt
prophylaxis
potassium
Prior art date
Application number
BRPI0518760A
Other languages
English (en)
Portuguese (pt)
Inventor
G Morrison Henry
M Belyk Kevin
Jones Philip
Summa Vincenzo
Original Assignee
St Di Ricerche Di Biologia Molecolare P Angeletti S P A
Merck & Co Inc
Merck Sharp & Dohme
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36171569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0518760(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by St Di Ricerche Di Biologia Molecolare P Angeletti S P A, Merck & Co Inc, Merck Sharp & Dohme, Schering Corp filed Critical St Di Ricerche Di Biologia Molecolare P Angeletti S P A
Publication of BRPI0518760A2 publication Critical patent/BRPI0518760A2/pt
Publication of BRPI0518760A8 publication Critical patent/BRPI0518760A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0518760A 2004-12-03 2005-12-02 sal de potássio do composto, e, composição farmacêutica BRPI0518760A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63313204P 2004-12-03 2004-12-03
PCT/US2005/043728 WO2006060712A2 (en) 2004-12-03 2005-12-02 Potassium salt of an hiv integrase inhibitor

Publications (2)

Publication Number Publication Date
BRPI0518760A2 BRPI0518760A2 (pt) 2008-12-09
BRPI0518760A8 true BRPI0518760A8 (pt) 2017-12-12

Family

ID=36171569

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518760A BRPI0518760A8 (pt) 2004-12-03 2005-12-02 sal de potássio do composto, e, composição farmacêutica

Country Status (35)

Country Link
US (2) US7754731B2 (https=)
EP (2) EP1819700B1 (https=)
JP (1) JP4705956B2 (https=)
KR (2) KR20130122031A (https=)
CN (1) CN101068793B (https=)
AR (2) AR052034A1 (https=)
AT (2) ATE518844T1 (https=)
AU (1) AU2005311671B8 (https=)
BR (1) BRPI0518760A8 (https=)
CA (1) CA2588398C (https=)
CR (1) CR9146A (https=)
CY (1) CY1112859T1 (https=)
DK (1) DK1819700T3 (https=)
EA (1) EA012418B1 (https=)
ES (2) ES2375788T3 (https=)
GE (1) GEP20105086B (https=)
HR (1) HRP20120066T1 (https=)
IL (1) IL183614A (https=)
MA (1) MA29120B1 (https=)
ME (1) ME01985B (https=)
MX (1) MX2007006639A (https=)
MY (1) MY144320A (https=)
NI (1) NI200700138A (https=)
NO (1) NO338784B1 (https=)
NZ (1) NZ555376A (https=)
PE (1) PE20061148A1 (https=)
PL (1) PL1819700T3 (https=)
PT (1) PT1819700E (https=)
RS (1) RS52197B (https=)
SI (1) SI1819700T1 (https=)
TN (1) TNSN07215A1 (https=)
TW (1) TWI344463B (https=)
UA (1) UA87884C2 (https=)
WO (2) WO2006060730A2 (https=)
ZA (1) ZA200704130B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20130810T1 (en) 2004-03-11 2013-09-30 4Sc Ag Sulphonylpyrroles as hdac inhibitors
RU2403066C2 (ru) * 2004-12-03 2010-11-10 Мерк Шарп Энд Домэ Корп Применение атазанавира для улучшения фармакокинетики лекарственных средств, метаболизируемых ugt1a1
EP1819323B2 (en) * 2004-12-03 2023-03-22 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
MX2007006635A (es) * 2004-12-03 2007-06-19 Merck & Co Inc Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion.
WO2007106768A2 (en) * 2006-03-14 2007-09-20 Merck & Co., Inc. Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use
EP2046328A4 (en) 2006-07-19 2009-10-28 Univ Georgia Res Found PYRIDINONE DIKETOIC ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY
WO2009009531A2 (en) * 2007-07-09 2009-01-15 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives for the treatment of hiv infections
CN101918372B (zh) * 2008-01-08 2014-03-26 默沙东公司 用于制备n-取代的羟基嘧啶酮羧酰胺类化合物的方法
US8742105B2 (en) 2009-06-02 2014-06-03 Hetero Research Foundation Polymorphs of raltegravir potassium
WO2011024192A2 (en) 2009-07-27 2011-03-03 Matrix Laboratories Ltd Novel polymorphs of raltegravir
IN2012DN03377A (https=) 2009-10-26 2015-10-23 Merck Sharp & Dohme
DE102009056636A1 (de) 2009-12-02 2011-06-09 Ratiopharm Gmbh Raltegravir-Polymorphe
WO2011071849A2 (en) * 2009-12-07 2011-06-16 University Of Georgia Research Foundation, Inc. Pyridinone hydroxycyclopentyl carboxamides: hiv integrase inhibitors with therapeutic applications
ES2362598B1 (es) * 2009-12-17 2012-06-13 Consejo Superior De Investigaciones Científicas (Csic) Uso del raltegravir y derivados para la elaboración de medicamentos destinados al tratamiento de infecciones por herpesvirus.
CA2999435A1 (en) * 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
CA2795157C (en) * 2010-04-01 2015-11-24 Teva Pharmaceutical Industries Ltd. Raltegravir salts and crystalline forms thereof
US8962833B2 (en) * 2010-05-25 2015-02-24 Hetero Research Foundation Salts of raltegravir
WO2012009446A1 (en) 2010-07-16 2012-01-19 Concert Pharmaceuticals Inc. Novel pyrimidinecarboxamide derivatives
CN101914067B (zh) * 2010-08-26 2012-07-11 陈岱岭 N-甲基嘧啶酮的合成方法
JO3209B1 (ar) * 2010-11-05 2018-03-08 H Lundbeck As طريقة لتصنيع نالتريكسون
WO2012103105A1 (en) 2011-01-24 2012-08-02 Assia Chemical Industries Ltd. Processes for preparing raltegravir and intermediates in the processes
WO2012106534A2 (en) * 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
WO2012137142A1 (en) 2011-04-06 2012-10-11 Lupin Limited Novel salts of raltegravir
CA2833006A1 (en) * 2011-04-22 2012-10-26 Merck Sharp & Dohme Corp. Taste-masked formulations of raltegravir
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
EP2522665A1 (en) 2011-05-03 2012-11-14 Sandoz Ag Crystalline sodium salt of an HIV integrase inhibitor
ES2450944T3 (es) 2011-06-01 2014-03-25 Ratiopharm Gmbh Composición y comprimido que comprenden raltegravir
WO2013037731A1 (de) 2011-09-16 2013-03-21 Hexal Ag Neue polymorphe form von raltegravir-kalium
CN103130787B (zh) * 2011-11-24 2015-06-10 南开大学 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
CN103130788B (zh) * 2011-11-24 2015-09-02 南开大学 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
ES2825029T3 (es) 2011-12-26 2021-05-14 Emcure Pharmaceuticals Ltd Síntesis de raltegravir
WO2013111100A1 (en) 2012-01-25 2013-08-01 Lupin Limited Stable amorphous raltegravir potassium premix and process for the preparation thereof
WO2014064711A2 (en) * 2012-10-22 2014-05-01 Hetero Research Foundation Methods of administering raltegravir and raltegravir compositions
EP2818470A1 (en) 2013-06-27 2014-12-31 Basf Se Cocrystals of raltegravir potassium
EP3022209B1 (en) * 2013-07-17 2018-03-07 ratiopharm GmbH Dolutegravir potassium salt
WO2015114608A1 (en) 2014-02-03 2015-08-06 Mylan Laboratories Ltd Processes for the preparation of intermediates of raltegravir
US10391178B2 (en) * 2014-03-21 2019-08-27 Mylan Laboratories Limited Premix of crystalline raltegravir potassium salt and a process for the preparation thereof
US10257840B2 (en) 2014-10-22 2019-04-09 Telefonaktiebolaget Lm Ericsson (Publ) Operation of wireless local area network in the presence of periodic interference
WO2016075605A1 (en) 2014-11-10 2016-05-19 Aurobindo Pharma Ltd An improved process for the preparation of raltegravir
EP3472134B1 (en) 2016-06-21 2021-10-20 Pharmathen S.A. Process for preparing compounds useful as intermediates for the preparation of raltegravir
JP2019529410A (ja) * 2016-09-15 2019-10-17 ルピン・リミテッド 純粋で安定な結晶のラルテグラビルカリウム３型の製造方法
CN108610338A (zh) * 2016-12-12 2018-10-02 天津国际生物医药联合研究院 一种嘧啶酮酰胺类化合物的制备方法
HRP20220613T1 (hr) 2017-11-14 2022-06-24 Cambrex Profarmaco Milano S.R.L. Postupak priprave raltegavira
WO2019236395A1 (en) * 2018-06-06 2019-12-12 Merck Sharp & Dohme Corp. Formulations of raltegravir
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
EP4093380A1 (en) 2020-01-23 2022-11-30 Lupin Limited Pharmaceutical compositions of raltegravir

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624391A5 (https=) * 1976-12-14 1981-07-31 Ciba Geigy Ag
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5717097A (en) * 1991-11-08 1998-02-10 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL121789A (en) * 1996-10-03 2001-06-14 Rohm & Haas A medicinal product for inhibiting mammalian cell tumors
JP3929244B2 (ja) * 1998-12-25 2007-06-13 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する芳香族ヘテロ環誘導体
IT1318424B1 (it) * 2000-03-24 2003-08-25 Unihart Corp Composti con attivita' anti-hiv.
CA2425440C (en) 2000-10-12 2010-04-13 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
GB0028483D0 (en) * 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
NZ533057A (en) * 2001-10-26 2005-11-25 Angeletti P Ist Richerche Bio N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CA2467718C (en) * 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP2161258A3 (en) * 2002-11-20 2010-04-07 Japan Tabacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
EP1578748B1 (en) * 2002-12-27 2010-09-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
RU2403066C2 (ru) 2004-12-03 2010-11-10 Мерк Шарп Энд Домэ Корп Применение атазанавира для улучшения фармакокинетики лекарственных средств, метаболизируемых ugt1a1
EP1819323B2 (en) 2004-12-03 2023-03-22 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
MX2007006635A (es) * 2004-12-03 2007-06-19 Merck & Co Inc Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion.

Also Published As

Publication number Publication date
MX2007006639A (es) 2007-06-19
AR052034A1 (es) 2007-02-28
EA200701204A1 (ru) 2007-12-28
EA012418B1 (ru) 2009-10-30
AR101429A2 (es) 2016-12-21
EP1819683A2 (en) 2007-08-22
RS52197B (sr) 2012-10-31
EP1819683B1 (en) 2011-08-03
WO2006060730A3 (en) 2006-08-17
ES2370136T3 (es) 2011-12-13
ES2375788T3 (es) 2012-03-06
CY1112859T1 (el) 2016-04-13
ATE534645T1 (de) 2011-12-15
EP1819700A2 (en) 2007-08-22
IL183614A0 (en) 2007-09-20
US8357798B2 (en) 2013-01-22
HRP20120066T1 (hr) 2012-03-31
CA2588398C (en) 2011-07-12
KR20070089990A (ko) 2007-09-04
JP2008521933A (ja) 2008-06-26
US7754731B2 (en) 2010-07-13
ZA200704130B (en) 2008-08-27
GEP20105086B (en) 2010-10-11
TNSN07215A1 (en) 2008-11-21
EP1819700B1 (en) 2011-11-23
US20060122205A1 (en) 2006-06-08
PL1819700T3 (pl) 2012-04-30
TWI344463B (en) 2011-07-01
CN101068793B (zh) 2011-05-25
WO2006060712A3 (en) 2006-09-21
WO2006060712A2 (en) 2006-06-08
IL183614A (en) 2012-03-29
ATE518844T1 (de) 2011-08-15
KR20130122031A (ko) 2013-11-06
ME01985B (me) 2012-10-31
US20100249410A1 (en) 2010-09-30
UA87884C2 (uk) 2009-08-25
NO338784B1 (no) 2016-10-17
NO20073404L (no) 2007-07-02
SI1819700T1 (sl) 2012-07-31
NZ555376A (en) 2009-11-27
MA29120B1 (fr) 2007-12-03
WO2006060730A2 (en) 2006-06-08
NI200700138A (es) 2008-05-13
PT1819700E (pt) 2012-02-01
TW200631944A (en) 2006-09-16
DK1819700T3 (da) 2012-03-19
HK1115011A1 (en) 2008-11-14
AU2005311671A1 (en) 2006-06-08
CN101068793A (zh) 2007-11-07
BRPI0518760A2 (pt) 2008-12-09
CR9146A (es) 2007-10-04
CA2588398A1 (en) 2006-06-08
MY144320A (en) 2011-08-29
AU2005311671B2 (en) 2011-01-27
KR101350420B1 (ko) 2014-02-17
PE20061148A1 (es) 2006-11-09
WO2006060712A9 (en) 2006-07-27
JP4705956B2 (ja) 2011-06-22
AU2005311671B8 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
BRPI0518760A8 (pt) sal de potássio do composto, e, composição farmacêutica
MX2023005984A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
JOP20210301A1 (ar) بيرولات ثلاثية الحلقة مكثفة كمُعدِّلات مضاد تريبسين ألفا-1
BR112012003578A8 (pt) Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal
BR0213522A (pt) Composto, composição farmacêutica, métodos de inibir a hiv integrase e para prevenir ou tratar a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids em um paciente, e, combinação útil para tratar ou prevenir a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids
EA200401437A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы для лечения вич инфекции, способ их получения (варианты), способ увеличения периода полупревращения ненуклеозидного соединения, обладающего активностью против ретровирусов, и способ получения фармацевтической композиции, обладающей специфичностью к лейкоцитам
BRPI0507628A (pt) composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
ATE423122T1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
MA38182A1 (fr) Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih)
EA200601654A1 (ru) Ингибиторы интегразы вич
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
EA202192433A1 (ru) Соединения, полезные в терапии вич
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
EA201100994A1 (ru) Способ получения производных бисфуранового спирта, соединения, соль, фармацевтическая композиция на ее основе, способ лечения или профилактики ретровирусных инфекций с ее помощью
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
MY144773A (en) 6-(heterocycle-susbtituted benzyl) -4-oxoquinoline compound and use of the same as hiv integrase inhibitor
PH12018501712A1 (en) Methods for treatment and prophylaxis of hiv and aids
BRPI0920605A8 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste.
BR112022020933A2 (pt) Inibidores de replicação do vírus da imunodeficiência humana
BRPI0719920B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

Free format text: ALTERADO DE: MERCK AND CO., INC.

B25A Requested transfer of rights approved

Owner name: SCHERING CORPORATION, (US)

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25C Requirement related to requested transfer of rights

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: MERCK SHARP AND DOHME CORP. (US)

B65X Notification of requirement for priority examination of patent application
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: SCHERING CORPORATION (US)

B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25E Requested change of name of applicant rejected

Owner name: SCHERING CORPORATION (US) ; ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO 020130028803 DE05/04/2013 DEVIDO AO DESPACHO PUBLICADO NA RPI 2635 DE 06/07/2021.

B25H Request for change of headquarter rejected

Owner name: SCHERING CORPORATION (US) ; ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE SEDE CONTIDO NA PETICAO 020130028804 DE05/04/2013 DEVIDO AO DESPACHO PUBLICADO NA RPI 2635 DE 06/07/2021.

B25B Requested transfer of rights rejected

Owner name: SCHERING CORPORATION (US) ; ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 020140034442 DE 18/11/2014DEVIDO AO DESPACHO PUBLICADO NA RPI 2635 DE 06/07/2021.